Role of nicotine dose and sensory cues in the regulation of smoke intake

doi:10.1016/0091-3057(93)90021-K

Pharmacology Biochemistry and Behavior

Volume 44, Issue 4, April 1993, Pages 891-900

https://doi.org/10.1016/0091-3057(93)90021-K Get rights and content

Abstract

We investigated the role of nicotine dose and sensory cues in the regulation of ad lib smoke intake. The smoking behavior of 12 adult male smokers was assessed in three conditions, presenting either high-nicotine cigarette smoke (high nicotine, high sensory), diluted cigarette smoke (low nicotine, low sensory), or an aerosol containing cigarette smoke constituents suspended in solution, which was low in nicotine, yet high in sensory impact. Subjects showed marked compensatory increases in smoking with the dilute smoke condition, whereas they puffed and inhaled the aerosol to a similar extent as the high-nicotine cigarette. Thus, subjects regulated their smoking behavior to equate sensory intensity rather than nicotine intake. Moreover, the aerosol and high-nicotine cigarette conditions lowered craving to a greater degree than the dilute smoke condition. Other mood indices, such as arousal and negative affect, were more effectively relieved by the high-nicotine dose condition. These results highlight the importance of sensory cues in the regulation of smoke intake and modulation of craving and suggest the clinical application of techniques for providing relief of cigarette craving during smoking cessation.

References (24)

F. Behm et al.
Low-nicotine regenerated smoke aerosol reduces desire for cigarettes
J. Subst. Abuse
(1990)
G. Colletti et al.
Assessment of the relationship between self-reported smoking rate and ecolyzer measurement
Addict. Behav.
(1982)
J. Henningfield et al.
Control of behavior by intravenous nicotine injections in human subjects
Pharmacol. Biochem. Behav.
(1983)
J.E. Herskovic et al.
Cigarette desirability and nicotine preference in smokers
Pharmacol. Biochem. Behav.
(1986)
E.D. Levin et al.
Development of a citric acid aerosol as a smoking cessation aid
Drug Alcohol Depend.
(1990)
J.E. Rose et al.
Refined cigarette smoke as a method for reducing nicotine intake
Pharmacol. Biochem. Behav.
(1987)
J.E. Rose et al.
Sensory blockade of smoking satisfaction
Pharmacol. Biochem. Behav.
(1985)
R.M. Stephens
Psychophysiological variables in cigarette smoking and reinforcing effects of nicotine
Addict. Behav.
(1977)
H. Ashton et al.
Smoking psychology and pharmacology
(1982)
Behm, F. M.; Schur, C.; Levin, E. D.; Tashkin, D. P.; Rose, J. E. Clinical evaluation of a citric acid inhaler for...

N.L. Benowitz et al.

Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking

J. Pharmacol. Exp. Ther.

(1990)

W.S. Cain

Sensory attributes to cigarette smoking

Cited by (118)

The incentive amplifying effects of nicotine: Roles in alcohol seeking and consumption
2022, Advances in Pharmacology
Nicotine has a unique profile among drugs of abuse. To the noninitiated user, nicotine has powerful aversive effects and its relatively weak euphorigenic effects undergo rapid tolerance. Despite this, nicotine is commonly abused despite negative heath consequences, and nicotine users have enormous difficulty quitting. Further, nicotine is one of the most commonly co-abused substances, in that it is often taken in combination with other drugs. One explanation of this polydrug use is that nicotine has multiple appetitive and consummatory conditioning effects. For example, nicotine is a reinforcement enhancer in that it can potently increase the incentive value of other stimuli, including those surrounding drugs of abuse such as alcohol. In addition, nicotine also has a unique profile of neurobiological effects that alter regulation of alcohol intake and interoception. This review discusses the psychological and biological mechanisms surrounding nicotine's appetitive conditioning and consummatory effects, particularly its interactions with alcohol.
Relation between tobacco smoking and pain: A narrative review of the scientific literature
2021, Revue des Maladies Respiratoires
Le tabac et la douleur possède une relation intime, complexe et à double sens. Cette revue narrative de la littérature a pour objectif de présenter l’état des connaissances sur cette relation entre tabac et douleur.
Le tabagisme (exposition chronique à la nicotine) est défini comme un facteur de risque de douleur chronique, et impliquant une sensibilisation nociceptive. Pour les patients tabagiques, la douleur sera un facteur motivationnel pour la consommation de tabac, et un obstacle au sevrage. Inversement, la nicotine (exposition aiguë) a des propriétés analgésiques clairement démontrées, et médiées notamment par l’activation des récepteurs nicotiniques.
La prise en charge de la douleur chez les patients tabagiques est encore largement sous-évaluée, et d’autres études seront nécessaires pour proposer des stratégies de sevrage efficaces. La nicotine et les modulateurs des récepteurs cholinergiques nicotiniques représentent des pistes innovantes pour la découverte de nouveaux analgésiques.
Les effets pernicieux du tabac sur la douleur, sensibilisation nociceptive chronique et analgésie aiguë, vont maintenir la consommation tabagique via un renforcement négatif. Une stratégie thérapeutique globale sera alors nécessaire pour accompagner le sevrage tabagique des patients douloureux.
Tobacco smoking and pain have an intimate, complex, two-way interaction. The purpose of this narrative review of the literature is to present what is currently understood about the relationship.
Tobacco smoking (and the associated chronic exposure to nicotine) has been defined as a risk factor for chronic pain, involving nociceptive sensitisation. For people who smoke, pain will be both a motivational factor for tobacco consumption and a barrier to tobacco use cessation. Conversely, nicotine (acute exposure) has clearly demonstrated analgesic properties, mediated in particular by activation of nicotinic acetylcholine receptors.
The management of pain in people who smoke is still largely unaddressed, and further studies will be needed to develop effective strategies for tobacco use cessation in this context. Nicotine and modulators of nicotinic acetylcholine receptors represent innovative strategies for the discovery of new analgesics.
The effects of smoking on pain, chronic nociceptive sensitisation and acute analgesia, serve to maintain tobacco consumption via negative reinforcement. A holistic therapeutic strategy is necessary to maximise the likelihood of successful smoking cessation.
Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction
2018, Biological Psychiatry
Tobacco smoking, driven by the addictive properties of nicotine, continues to be a worldwide health problem. Based on the well-established role of glutamatergic neurotransmission in drug addiction, novel medication development strategies seek to halt nicotine consumption and prevent relapse to tobacco smoking by modulating glutamate transmission. The presynaptic inhibitory metabotropic glutamate receptors 2 and 3 (mGluR2/3) are key autoreceptors on glutamatergic terminals that maintain glutamate homeostasis. Accumulating evidence suggests the critical role of mGluR2/3 in different aspects of nicotine addiction, including acquisition and maintenance of nicotine taking, nicotine withdrawal, and persistent nicotine seeking even after prolonged abstinence. The involvement of mGluR2/3 in other neuropsychiatric conditions, such as anxiety, depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease, and pain, provides convincing evidence suggesting that mGluR2/3 may provide an effective therapeutic approach for comorbidity of smoking and these conditions. This focused review article highlights that mGluR2/3 provide a promising target in the search for smoking cessation medication with novel mechanisms of actions that differ from those of currently U.S. Food and Drug Administration–approved pharmacotherapies.
How can we Improve on Modeling Nicotine Addiction to Develop Better Smoking Cessation Treatments?
2016, International Review of Neurobiology
Citation Excerpt :
This suggests that future IVSA models may need to look into coadministration studies for potential synergistic effects with nicotinic receptor antagonists and blocking other targets to have maximal efficacy in humans (Engleman, Rodd, Bell, & Murphy, 2008; Kuwabara, Heishman, Brasic, Contoreggi, et al., 2014). It has been well documented that sensory cues associated with tobacco smoking enhance the primary reinforcing effects of nicotine in smokers (Rose, Behm, & Levin, 1993). This has been shown to include the sensory effects in the larynx caused by particles in the tobacco smoke as well as paraphernalia associated with tobacco smoking such as the visual cues of cigarettes or the act of rolling up a cigarette before smoking.
Clinically effective smoking cessation treatments are few in number, mainly varenicline, bupropion, and nicotine replacement therapy being prescribed by health organizations. Of the many compounds tested for smoking cessation, a good proportion fail in human trials despite positive findings in rodents. This chapter aims to cover the uses and some pit falls of current methodologies employed to discover clinical treatments in the laboratory. Complicating factors include the complex nature of genetics in tobacco smoking and the comorbidity associated with other psychiatric disorders, which has not been addressed fully in the rodent laboratory. This chapter reviews the evidence from intravenous nicotine self-administration studies and proposes modifications on how we can improve the validity of the animal models by incorporating clinically relevant factors considered to be critical in tobacco smoking. For example, choice procedures that incorporate alternative reinforcers, use of reinstatement models, and second-order schedules of reinforcement are proposed to have better scientific validity that may lead to better clinical outcomes. Furthermore, improved experimental methods will also improve our chances of discovering effective treatments that ultimately may mitigate the effects of tobacco smoking with regard to health worldwide.
Baseline impulsive choice predicts the effects of nicotine and nicotine withdrawal on impulsivity in rats
2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Impulsive choice, a form of impulsivity, is associated with tobacco smoking in humans. Trait impulsivity may be a vulnerability factor for smoking, or smoking may lead to impulsive behaviors. We investigated the effects of 14-day nicotine exposure (6.32 mg/kg/day base, subcutaneous minipumps) and spontaneous nicotine withdrawal on impulsive choice in low impulsive (LI) and high impulsive (HI) rats. Impulsive choice was measured in the delayed reward task in which rats choose between a small immediate reward and a large delayed reward. HI and LI rats were selected from the highest and lowest quartiles of the group before exposure to nicotine. In non-selected rats, nicotine or nicotine withdrawal had no effect on impulsive choice. In LI rats, chronic nicotine exposure decreased preference for the large reward with larger effects at longer delays, indicating increased impulsive choice. Impulsive choices for the smaller immediate rewards continued to increase during nicotine withdrawal in LI rats. In HI rats, nicotine exposure and nicotine withdrawal had no effect on impulsive choice, although there was a tendency for decreased preference for the large reward at short delays. These results indicate that nicotine- and nicotine withdrawal-induced increases in impulsive choice depend on trait impulsivity with more pronounced increases in impulsive choice in LI compared to HI subjects. Increased impulsivity during nicotine exposure may strengthen the addictive properties of nicotine and contribute to compulsive nicotine use.
Electronic cigarettes for smoking cessation
2024, Cochrane Database of Systematic Reviews

View all citing articles on Scopus

View full text

Role of nicotine dose and sensory cues in the regulation of smoke intake

Abstract

J. Subst. Abuse

Addict. Behav.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Drug Alcohol Depend.

Pharmacol. Biochem. Behav.

Pharmacol. Biochem. Behav.

Addict. Behav.

Smoking psychology and pharmacology

Intravenous nicotine replacement suppresses nicotine intake from cigarette smoking

J. Pharmacol. Exp. Ther.

Sensory attributes to cigarette smoking